{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T18:10:32Z","timestamp":1764785432388},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,18]]},"DOI":"10.7759\/cureus.62606","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T13:59:54Z","timestamp":1718719194000},"source":"Crossref","is-referenced-by-count":4,"title":["Effectiveness of Direct Oral Anticoagulants and Vitamin K Antagonists in Preventing Stroke in Patients With Atrial Fibrillation and Liver Cirrhosis: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Tanya","family":"Sinha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mandeep","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abshiro H","family":"Mayow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thin M","family":"Soe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaldoun","family":"Khreis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandipkumar S","family":"Chaudhari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samer","family":"Kholoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shamsha","family":"Hirani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k2817","article-title":"Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study","volume":"362","author":"Tapper EB","year":"2018","unstructured":"Tapper EB, Parikh ND. Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study. BMJ. 2018, 362:k2817. 10.1136\/bmj.k2817","journal-title":"BMJ"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes C","year":"2018","unstructured":"Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018, 67:123-33. 10.1002\/hep.29466","journal-title":"Hepatology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study","volume":"285","author":"Go AS","year":"2001","unstructured":"Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA. 2001, 285:2370-5. 10.1001\/jama.285.18.2370","journal-title":"JAMA"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.117.309732","article-title":"Atrial fibrillation: epidemiology, pathophysiology, and clinical outcomes","volume":"120","author":"Staerk L","year":"2017","unstructured":"Staerk L, Sherer JA, Ko D, Benjamin EJ, Helm RH. Atrial fibrillation: epidemiology, pathophysiology, and clinical outcomes. Circ Res. 2017, 120:1501-17. 10.1161\/CIRCRESAHA.117.309732","journal-title":"Circ Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2022.04.023","article-title":"Comparing atrial fibrillation guidelines: focus on stroke prevention, bleeding risk assessment and oral anticoagulant recommendations","volume":"101","author":"Imberti JF","year":"2022","unstructured":"Imberti JF, Mei DA, Vitolo M, et al.. Comparing atrial fibrillation guidelines: focus on stroke prevention, bleeding risk assessment and oral anticoagulant recommendations. Eur J Intern Med. 2022, 101:1-7. 10.1016\/j.ejim.2022.04.023","journal-title":"Eur J Intern Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-023-00598-1","article-title":"Direct oral anticoagulants versus vitamin K antagonists in cirrhotic patients with atrial fibrillation: update of systematic review and meta-analysis","volume":"23","author":"Hu T","year":"2023","unstructured":"Hu T, Li YH, Han WQ, Maduray K, Chen TS, Hao L, Zhong JQ. Direct oral anticoagulants versus vitamin K antagonists in cirrhotic patients with atrial fibrillation: update of systematic review and meta-analysis. Am J Cardiovasc Drugs. 2023, 23:683-94. 10.1007\/s40256-023-00598-1","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1160\/TH13-06-0443","article-title":"Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease","volume":"110","author":"De Caterina R","year":"2013","unstructured":"De Caterina R, Husted S, Wallentin L, et al.. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost. 2013, 110:1087-107. 10.1160\/TH13-06-0443","journal-title":"Thromb Haemost"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-5-200909010-00003","article-title":"The net clinical benefit of warfarin anticoagulation in atrial fibrillation","volume":"151","author":"Singer DE","year":"2009","unstructured":"Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, Go AS. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 2009, 151:297-305. 10.7326\/0003-4819-151-5-200909010-00003","journal-title":"Ann Intern Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.28763","article-title":"Comparison of direct oral anticoagulants and warfarin in the prevention of stroke in patients with valvular heart disease: a meta-analysis","volume":"14","author":"Batool S","year":"2022","unstructured":"Batool S, Chaudhari SS, Shaik TA, et al.. Comparison of direct oral anticoagulants and warfarin in the prevention of stroke in patients with valvular heart disease: a meta-analysis. Cureus. 2022, 14:e28763. 10.7759\/cureus.28763","journal-title":"Cureus"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2016.06.003","article-title":"Bleeding with direct oral anticoagulants vs warfarin: clinical experience","volume":"129","author":"Eikelboom J","year":"2016","unstructured":"Eikelboom J, Merli G. Bleeding with direct oral anticoagulants vs warfarin: clinical experience. Am J Med. 2016, 129:S33-40. 10.1016\/j.amjmed.2016.06.003","journal-title":"Am J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII - renewing consensus in portal hypertension","volume":"76","author":"de Franchis R","year":"2022","unstructured":"de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C. Baveno VII - renewing consensus in portal hypertension. J Hepatol. 2022, 76:959-74. 10.1016\/j.jhep.2021.12.022","journal-title":"J Hepatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.5114\/ceh.2023.130605","article-title":"Assessment of the efficiency and safety of anti-coagulation therapy in patients with liver cirrhosis and atrial fibrillation","volume":"9","author":"Baylo A","year":"2023","unstructured":"Baylo A, Cherniavskyi V, Reshotko D. Assessment of the efficiency and safety of anti-coagulation therapy in patients with liver cirrhosis and atrial fibrillation. Clin Exp Hepatol. 2023, 9:265-71. 10.5114\/ceh.2023.130605","journal-title":"Clin Exp Hepatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1101\/2023.12.05.23299538","article-title":"Efficacy and safety of direct oral anticoagulants versus Warfarin in patients with non-valvular atrial fibrillation and liver cirrhosis","volume":"6","author":"Chou TS","year":"2023","unstructured":"Chou TS, Lin Y, Tsai ML, et al.. Efficacy and safety of direct oral anticoagulants versus Warfarin in patients with non-valvular atrial fibrillation and liver cirrhosis. medRxiv. 2023, 6:2023-12. 10.1101\/2023.12.05.23299538","journal-title":"medRxiv"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2024.03.024","article-title":"Effectiveness and safety of direct oral anticoagulants among patients with non-valvular atrial fibrillation and liver disease: a multinational cohort study","volume":"237","author":"Douros A","year":"2024","unstructured":"Douros A, Cui Y, Platt RW, Filion KB, Sebastiani G, Renoux C. Effectiveness and safety of direct oral anticoagulants among patients with non-valvular atrial fibrillation and liver disease: a multinational cohort study. Thromb Res. 2024, 237:71-8. 10.1016\/j.thromres.2024.03.024","journal-title":"Thromb Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13045","article-title":"Safety of direct oral anticoagulants vs warfarin in patients with chronic liver disease and atrial fibrillation","volume":"100","author":"Goriacko P","year":"2018","unstructured":"Goriacko P, Veltri KT. Safety of direct oral anticoagulants vs warfarin in patients with chronic liver disease and atrial fibrillation. Eur J Haematol. 2018, 100:488-93. 10.1111\/ejh.13045","journal-title":"Eur J Haematol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.060687","article-title":"Comparative effectiveness and safety of direct oral anticoagulants and warfarin in patients with atrial fibrillation and chronic liver disease: a nationwide cohort study","volume":"147","author":"Lawal OD","year":"2023","unstructured":"Lawal OD, Aronow HD, Shobayo F, et al.. Comparative effectiveness and safety of direct oral anticoagulants and warfarin in patients with atrial fibrillation and chronic liver disease: a nationwide cohort study. Circulation. 2023, 147:782-94. 10.1161\/CIRCULATIONAHA.122.060687","journal-title":"Circulation"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.011112","article-title":"Effectiveness and safety of non-vitamin K antagonist oral anticoagulant and warfarin in cirrhotic patients with nonvalvular atrial fibrillation","volume":"8","author":"Lee HF","year":"2019","unstructured":"Lee HF, Chan YH, Chang SH, et al.. Effectiveness and safety of non-vitamin K antagonist oral anticoagulant and warfarin in cirrhotic patients with nonvalvular atrial fibrillation. J Am Heart Assoc. 2019, 8:e011112. 10.1161\/JAHA.118.011112","journal-title":"J Am Heart Assoc"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.04.052","article-title":"Direct oral anticoagulants in patients with atrial fibrillation and liver disease","volume":"73","author":"Lee SR","year":"2019","unstructured":"Lee SR, Lee HJ, Choi EK, et al.. Direct oral anticoagulants in patients with atrial fibrillation and liver disease. J Am Coll Cardiol. 2019, 73:3295-308. 10.1016\/j.jacc.2019.04.052","journal-title":"J Am Coll Cardiol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31264","article-title":"Mortality and hepatic decompensation in patients with cirrhosis and atrial fibrillation treated with anticoagulation","volume":"73","author":"Serper M","year":"2021","unstructured":"Serper M, Weinberg EM, Cohen JB, Reese PP, Taddei TH, Kaplan DE. Mortality and hepatic decompensation in patients with cirrhosis and atrial fibrillation treated with anticoagulation. Hepatology. 2021, 73:219-32. 10.1002\/hep.31264","journal-title":"Hepatology"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad655.548","article-title":"Safety and efficacy of anticoagulation for atrial fibrillation in cirrhotic patients","volume":"44","author":"Song JJ","year":"2023","unstructured":"Song JJ, Boulier K, Shang H, Jackson NJ, Shetty A, Xia V, Honda HM. Safety and efficacy of anticoagulation for atrial fibrillation in cirrhotic patients. Eur Heart J. 2023, 44:10.1093\/eurheartj\/ehad655.548","journal-title":"Eur Heart J"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2020.622","article-title":"Safety of direct oral anticoagulants compared to warfarin in cirrhotic patients with atrial fibrillation","volume":"37","author":"Yoo SY","year":"2022","unstructured":"Yoo SY, Kim E, Nam GB, et al.. Safety of direct oral anticoagulants compared to warfarin in cirrhotic patients with atrial fibrillation. Korean J Intern Med. 2022, 37:555-66. 10.3904\/kjim.2020.622","journal-title":"Korean J Intern Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.005307","article-title":"Liver cirrhosis in patients with atrial fibrillation: would oral anticoagulation have a net clinical benefit for stroke prevention?","volume":"6","author":"Kuo L","year":"2017","unstructured":"Kuo L, Chao TF, Liu CJ, et al.. Liver cirrhosis in patients with atrial fibrillation: would oral anticoagulation have a net clinical benefit for stroke prevention?. J Am Heart Assoc. 2017, 6:10.1161\/JAHA.116.005307","journal-title":"J Am Heart Assoc"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2019.02.006","article-title":"Anticoagulation in the cirrhotic patient","volume":"1","author":"Turco L","year":"2019","unstructured":"Turco L, de Raucourt E, Valla DC, Villa E. Anticoagulation in the cirrhotic patient. JHEP Rep. 2019, 1:227-39. 10.1016\/j.jhepr.2019.02.006","journal-title":"JHEP Rep"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26372","article-title":"An unbalance between von Willebrand factor and ADAMTS13 in acute liver failure: implications for hemostasis and clinical outcome","volume":"58","author":"Hugenholtz GC","year":"2013","unstructured":"Hugenholtz GC, Adelmeijer J, Meijers JC, Porte RJ, Stravitz RT, Lisman T. An unbalance between von Willebrand factor and ADAMTS13 in acute liver failure: implications for hemostasis and clinical outcome. Hepatology. 2013, 58:752-61. 10.1002\/hep.26372","journal-title":"Hepatology"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27783","article-title":"Impact of anticoagulation on upper-gastrointestinal bleeding in cirrhosis: a retrospective multicenter study","volume":"62","author":"Cerini F","year":"2015","unstructured":"Cerini F, Gonzalez JM, Torres F, et al.. Impact of anticoagulation on upper-gastrointestinal bleeding in cirrhosis: a retrospective multicenter study. Hepatology. 2015, 62:575-83. 10.1002\/hep.27783","journal-title":"Hepatology"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2292","article-title":"Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th Ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Ageno W","year":"2012","unstructured":"Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th Ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012, 141:e44S-88S. 10.1378\/chest.11-2292","journal-title":"Chest"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.10.1095","article-title":"Systematic overview of warfarin and its drug and food interactions","volume":"165","author":"Holbrook AM","year":"2005","unstructured":"Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005, 165:1095-106. 10.1001\/archinte.165.10.1095","journal-title":"Arch Intern Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.2217\/fca.14.13","article-title":"Atrial fibrillation and quality of life related to disease and treatment: focus on anticoagulation","volume":"10","author":"Ynsaurriaga FA","year":"2014","unstructured":"Ynsaurriaga FA, Peinado RP, Ormaetxe Merodio JM. Atrial fibrillation and quality of life related to disease and treatment: focus on anticoagulation. Future Cardiol. 2014, 10:381-93. 10.2217\/fca.14.13","journal-title":"Future Cardiol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-016-0185-9","article-title":"Patient preferences for oral anticoagulation therapy in atrial fibrillation: a systematic literature review","volume":"10","author":"Wilke T","year":"2017","unstructured":"Wilke T, Bauer S, Mueller S, Kohlmann T, Bauersachs R. Patient preferences for oral anticoagulation therapy in atrial fibrillation: a systematic literature review. Patient. 2017, 10:17-37. 10.1007\/s40271-016-0185-9","journal-title":"Patient"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.20524\/aog.2022.0745","article-title":"Anticoagulation in patients with atrial fibrillation and liver cirrhosis","volume":"35","author":"Karapedi E","year":"2022","unstructured":"Karapedi E, Papadopoulos N, Trifylli EM, Koustas E, Deutsch M, Aloizos G. Anticoagulation in patients with atrial fibrillation and liver cirrhosis. Ann Gastroenterol. 2022, 35:557-67. 10.20524\/aog.2022.0745","journal-title":"Ann Gastroenterol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/262912-effectiveness-of-direct-oral-anticoagulants-and-vitamin-k-antagonists-in-preventing-stroke-in-patients-with-atrial-fibrillation-and-liver-cirrhosis-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T13:59:57Z","timestamp":1718719197000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/262912-effectiveness-of-direct-oral-anticoagulants-and-vitamin-k-antagonists-in-preventing-stroke-in-patients-with-atrial-fibrillation-and-liver-cirrhosis-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,18]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.62606","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,18]]}}}